Rates and Predictors of Vaccinations Among Inflammatory Bowel Disease Patients Receiving Anti-Tumor Necrosis Factor Agents
- PMID: 28836068
- DOI: 10.1007/s10620-017-4716-6
Rates and Predictors of Vaccinations Among Inflammatory Bowel Disease Patients Receiving Anti-Tumor Necrosis Factor Agents
Abstract
Background: As an important quality measure, the rates of recommended immunizations among immunocompromised inflammatory bowel disease (IBD) patients in community practice have not been well studied.
Aims: This study sought to investigate the rates and predictors of recommended immunizations and screening tests among IBD patients receiving anti-tumor necrosis factor (TNF) therapy in a large integrated healthcare organization.
Methods: We conducted a retrospective cohort study of 1401 IBD patients on anti-TNF therapy between 2010 and 2013 within the Kaiser Permanente Northern California healthcare system. The rates of vaccinations and screening tests were quantified, and the associated predictors were investigated.
Results: Vaccination rates for influenza and pneumococcus were 43.5 and 24.1%, respectively. The majority of patients (73.7%) received hepatitis B screening and/or vaccine. Patients receiving infliximab had higher rates of pneumococcal vaccine (P = 0.002), hepatitis B screening (P < 0.001), and tuberculin skin test (P < 0.001) compared with patients receiving adalimumab. Older patient age (≥50 years) was associated with higher likelihood of having HBsAg test (odds ratio [OR] 1.5, 95% confidence interval [CI] 1.2-2.0, P = 0.002), influenza vaccine (OR 2.6 [2.1-3.4], P < 0.001), and pneumococcal vaccine (OR 4.0 [3.0-5.3], P < 0.001). In contrast, older providers (≥50 years) were associated with significantly lower likelihood of their patients' having hepatitis A and B screening tests, and pneumococcal vaccination.
Conclusions: The rates of immunizations for IBD patients receiving anti-TNF treatment were lower than recommended. Structured reminders for vaccinations and education for both patients and providers (older physicians in particular) may prove beneficial in improving immunization rates among immunocompromised IBD patients.
Keywords: Anti-TNF agents; Biologic therapy; Inflammatory bowel disease; Vaccination.
Comment in
-
Lax Prophylaxis: Vaccinating the Inflammatory Bowel Disease Patient.Dig Dis Sci. 2018 Jan;63(1):4-6. doi: 10.1007/s10620-017-4836-z. Dig Dis Sci. 2018. PMID: 29127607 No abstract available.
Similar articles
-
A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.Int J Mol Sci. 2019 May 23;20(10):2529. doi: 10.3390/ijms20102529. Int J Mol Sci. 2019. PMID: 31126015 Free PMC article. Review.
-
Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.Dig Liver Dis. 2017 Oct;49(10):1086-1091. doi: 10.1016/j.dld.2017.07.010. Epub 2017 Aug 1. Dig Liver Dis. 2017. PMID: 28826571
-
Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study.Inflamm Bowel Dis. 2012 Jun;18(6):1042-7. doi: 10.1002/ibd.21800. Epub 2011 Jun 14. Inflamm Bowel Dis. 2012. PMID: 21674732 Clinical Trial.
-
Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.Dig Dis Sci. 2018 Jun;63(6):1583-1591. doi: 10.1007/s10620-018-5020-9. Epub 2018 Mar 21. Dig Dis Sci. 2018. PMID: 29564674
-
Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease.World J Gastroenterol. 2015 Oct 28;21(40):11273-81. doi: 10.3748/wjg.v21.i40.11273. World J Gastroenterol. 2015. PMID: 26527572 Free PMC article. Review.
Cited by
-
Uptake of influenza vaccination among persons with inflammatory bowel disease, multiple sclerosis or rheumatoid arthritis: a population-based matched cohort study.CMAJ Open. 2021 May 14;9(2):E510-E521. doi: 10.9778/cmajo.20200105. Print 2021 Apr-Jun. CMAJ Open. 2021. PMID: 33990365 Free PMC article.
-
Prevalence Rates of Pneumococcal Vaccination in IBD and 30-Day Clinical Outcomes in Patients With IBD and Pneumococcal Disease Stratified by Receipt of Pneumococcal Vaccination: A Multi-Network Study.Crohns Colitis 360. 2023 Dec 8;5(4):otad048. doi: 10.1093/crocol/otad048. eCollection 2023 Oct. Crohns Colitis 360. 2023. PMID: 38077746 Free PMC article. No abstract available.
-
Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 1: Live Vaccines.J Can Assoc Gastroenterol. 2021 Jul 29;4(4):e59-e71. doi: 10.1093/jcag/gwab015. eCollection 2021 Aug. J Can Assoc Gastroenterol. 2021. PMID: 34476338 Free PMC article. Review.
-
Lax Prophylaxis: Vaccinating the Inflammatory Bowel Disease Patient.Dig Dis Sci. 2018 Jan;63(1):4-6. doi: 10.1007/s10620-017-4836-z. Dig Dis Sci. 2018. PMID: 29127607 No abstract available.
-
Improving immunization strategies in patients with inflammatory bowel disease.Ann Gastroenterol. 2019 May-Jun;32(3):247-256. doi: 10.20524/aog.2019.0351. Epub 2019 Jan 15. Ann Gastroenterol. 2019. PMID: 31040621 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials